Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Invested Capital (2016 - 2026)

Anika Therapeutics has reported Invested Capital over the past 17 years, most recently at $133.9 million for Q1 2026.

  • Quarterly Invested Capital fell 9.77% to $133.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $133.9 million through Mar 2026, down 9.77% year-over-year, with the annual reading at $143.5 million for FY2025, 6.83% down from the prior year.
  • Invested Capital was $133.9 million for Q1 2026 at Anika Therapeutics, down from $143.5 million in the prior quarter.
  • Over five years, Invested Capital peaked at $290.5 million in Q2 2022 and troughed at $133.9 million in Q1 2026.
  • The 5-year median for Invested Capital is $210.3 million (2024), against an average of $215.2 million.
  • Year-over-year, Invested Capital dropped 2.0% in 2022 and then plummeted 33.5% in 2024.
  • A 5-year view of Invested Capital shows it stood at $285.6 million in 2022, then dropped by 25.67% to $212.3 million in 2023, then dropped by 27.45% to $154.0 million in 2024, then dropped by 6.83% to $143.5 million in 2025, then fell by 6.67% to $133.9 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Invested Capital are $133.9 million (Q1 2026), $143.5 million (Q4 2025), and $146.8 million (Q3 2025).